Status:
COMPLETED
Pilot Medical Evaluation of the T50 Test
Lead Sponsor:
Fresenius Medical Care Deutschland GmbH
Conditions:
Renal Failure
Cardiovascular Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This pilot study aims to evaluate in an exploratory way the predictive power of a novel in vitro test (T50 Calcification Inhibition Test, T50 CIT), which measures the mineralization inhibition capacit...
Detailed Description
Disturbances in mineral and bone metabolism centrally contribute to the exceedingly elevated risk for cardiovascular (CV) disease in dialysis patients. A novel in vitro test (T50 Calcification Inhibit...
Eligibility Criteria
Inclusion
- Informed consent signed and dated by study patient and investigator/authorised physician
- Minimum age of 18 years
- Incident and prevalent haemodialysis patients
- Three haemodialysis treatments per week
Exclusion
- Any condition which could interfere with the patient's ability to comply with the study
- Pregnancy (pregnancy test will be conducted with female patients aged \<= 55 years) or lactation period
- Participation in an interventional clinical study during the preceding 30 days
Key Trial Info
Start Date :
September 22 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 4 2020
Estimated Enrollment :
776 Patients enrolled
Trial Details
Trial ID
NCT03292029
Start Date
September 22 2017
End Date
March 4 2020
Last Update
February 9 2022
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro de Diálisis Barcelona - Glories
Barcelona, Spain, 08013
2
Centro de Diálisis Barcelona - Diagonal
Barcelona, Spain, 08019
3
Centro de Diálisis Barcelona - Rosselló
Barcelona, Spain, 08029
4
Centro de Diálisis Granollers
Granollers, Spain, 08401